Peer to peer review on Glaucoma

Source audio-visual aids (Power Point® Presentation) provided by Allergan India Ltd. with the exception to item 1 which is the property of Dr. Ravin Das

Speakers for the session:

1. Introduction and Target Intra-ocular pressure - Dr. Ravin Das
2. The role of intra-ocular pressure in glaucoma (Landmark studies in Glaucoma) - Dr. Shabbir Hussain (Slide 1-28)
3. Implementing what we have learnt - Dr. Major Avinash Mishra (Slide 29-50)
4. Achieving the targets set by the studies & reaching difficult target pressures - Dr. Rahul Shukla (Slide 51-85)
5. Lumigan™ the Indian experience (L.E.E.D) - Dr. Shabbir Hussain. (Slide 86-100)
6. Expert/critical comments on all of the above - Professor Emeritus Dr. R. K. Mishra

Note: Clicking on the above links will open a new window in which the referenced Power Point® presentation will be downloaded. Please be patient in case of item 2 through 5 since the file is 3.6 MB.

Expert/critical comments on the session

Professor Emeritus Dr. R. K. Mishra

It was due to Dr. Mrs. Meeta Shrivastava's inability to attend the session that Professor R. K. Mishra was requested to provide his valuable comments based on his vast clinical experience.

Commenting on the above:

1. Pilocarpine is no longer a favored drug in the treatment of POAG. However since the incidence of Narrow or Closed angle glaucoma is quite high in Indian eyes the drug may not be disregarded.
2. Bimatoprost is an excellent drugs, however the patient must be educated about the side effects, especially about the tendency to cause "redness" and "eyelash growth". Darkening of the iris pigment may not be overlooked.
3. When target intra-ocular pressure is not achieved by medications in the form of monotherapy or combination therapy never hesitate for surgery.
4. The main drawback of Latanoprost being the requirement of low storage temperature.
5. Topical Acetazolamide is of no use, however oral acetazolamide has its place in Glaucoma therapy.